Jupiter Neurosciences Inc. (NASDAQ: JUNS) completed a registered direct offering that raised approximately $2.0 million in gross proceeds through the sale of 7,142,858 shares of common stock.

The clinical-stage biopharmaceutical company, which focuses on central nervous system disorders and neuroinflammation, said the funds will be used to finance its Parkinson's disease program and reduce debt.

"We were able to significantly reduce our debt, which improves our balance sheet; and with this capital in hand, we can comfortably execute on the Parkinson's Phase 2a trial," said Christer Rosén, Chairman and CEO of Jupiter Neurosciences.

The company is conducting a Phase 2a clinical trial called RESET, which evaluates its JOTROL formulation in Parkinson's disease patients. JOTROL is described as a proprietary, enhanced bioavailability resveratrol formulation.

Jupiter Neurosciences received an Investigational New Drug application approval from regulators in November 2025 for the Parkinson's program. The multi-center, randomized, double-blind, placebo-controlled study is registered on ClinicalTrials.gov.

The company also mentioned plans to work toward completing a transaction involving PharmALA's ALA-002-MDMA compound.

D. Boral Capital LLC served as the placement agent for the registered direct offering. The company filed a prospectus supplement with the Securities and Exchange Commission describing the terms of the offering.